MedTrace Logo

Cost of Cancer Diagnosis Using Next-generation Sequencing Targeted Gene Panels in Routine Practice

NCT04656717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2020-12-07

No results posted yet for this study

Summary

The aim of this study was to measure the total cost of performing next-generation sequencing (NGS) in clinical practice in France, in both germline and somatic cancer genetics.

The study was performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost was estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. A top-down methodology for specific post-sequencing steps was used.

Additional non-specific costs were also included and costs were detailed per step of the process.

Conditions

Interventions

OTHER

Measure of the total cost of performing next-generation sequencing (NGS)

Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.

Sponsors & Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

    lead NETWORK

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-11-30
Completion
2015-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04656717 on ClinicalTrials.gov